Federal Research Institute Of Pediatric Hematology, Oncology And Immunology
Clinical trials sponsored by Federal Research Institute Of Pediatric Hematology, Oncology And Immunology, explained in plain language.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Immune booster: donor NK cells aim to stop leukemia return after transplant Results expected Oct 2026 (estimated)
- New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens Results expected Dec 2026 (estimated)
- New cell cocktail aims to prevent transplant complications in kids with leukemia Results expected Jun 2027 (estimated)
-
New hope for kids with aggressive nerve cancer: immune-boosting combo trial opens
Disease control Recruiting nowThis phase 3 trial tests a powerful mix of chemotherapy, immunotherapy, and the child's own natural killer (NK) cells for children aged 1.5 to 18 with high-risk neuroblastoma that didn't respond or came back. The goal is to shrink tumors and improve survival by helping the immune…
Phase 3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 09:00 UTC
-
New cell cocktail aims to prevent transplant complications in kids with leukemia
Disease control Recruiting nowThis study tests a new method to prevent graft-versus-host disease (GVHD) in children and young adults with high-risk blood cancers who need a stem cell transplant from a half-matched donor. The approach combines specially enriched donor immune cells with a stem cell graft that h…
Phase 2/3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:14 UTC
-
Immune booster: donor NK cells aim to stop leukemia return after transplant
Disease control Recruiting nowThis clinical trial tests whether infusions of donor natural killer (NK) cells, given before and after a stem cell transplant, can safely prevent leukemia from coming back in children and young adults with hard-to-treat acute leukemia. The study enrolls 15 patients aged 0 to 25 w…
Phase 2 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 08:00 UTC
-
New chemo regimen aims to boost survival in kids with down syndrome and leukemia
Disease control Recruiting nowThis study is testing a specific set of four chemotherapy blocks in children (0-18 years) who have both acute myeloid leukemia (AML) and Down syndrome. The goal is to see if this tailored treatment can improve long-term survival and reduce harsh side effects compared to past appr…
Phase 3 • Sponsor: Federal Research Institute of Pediatric Hematology, Oncology and Immunology • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC